DermaVue SuperHuman Program
Lose Belly Fat. Keep Your Muscle.
Doctor-supervised weight loss with Ozempic, Mounjaro & Wegovy — now in Kerala & Coimbatore.
Why Indians Gain Weight Differently
The “Thin-Fat Indian” Problem
Research shows one-third of Indians with “normal” weight carry dangerous levels of hidden visceral fat.
Same BMI. Completely different health risk.
Source: Yajnik CS, The Lancet, 2004 — “The thin-fat Indian baby: differences in body composition and metabolic risk between Indian and Caucasian populations.”
The New Indian BMI Standards
| Category | Indian Cutoff | International |
|---|---|---|
| Normal | Below 23 | Below 25 |
| Overweight | 23 – 24.9 | 25 – 29.9 |
| Obese | 25 and above | 30 and above |
How the SuperHuman Program Works
WhatsApp / Online Inquiry
Reach out via WhatsApp or our booking form. Our coordinator will collect basic health details and schedule your first consultation.
Dietitian Consultation (45–60 min)
A comprehensive nutrition and lifestyle assessment covering diet history, eating patterns, activity level, and metabolic risk screening.
Mandatory Lab Panel
HbA1c, Fasting Insulin, HOMA-IR, Complete Lipids, TSH, LFT, eGFR, Vitamin D3, and B12. Lab form sent after the dietitian consultation.
Dermatologist Medical Clearance
Your dermatologist reviews labs, assesses skin health baseline, and confirms GLP-1 eligibility with a personalized dosing plan.
GLP-1 Therapy Initiation
Start Mounjaro (Tirzepatide) or Ozempic (Semaglutide) at the lowest effective dose with structured titration under medical supervision.
Monthly Follow-Up + Body Composition
Track fat loss vs. muscle retention with body composition monitoring. Dose adjustments, nutrition refinements, and side-effect management each month.
Face-Saver Protocol
DermaVue’s dermatology advantage: Profhilo, Polynucleotides, and MFU-V/Ultherapy to prevent and reverse facial volume loss from rapid weight loss.
Your GLP-1 Treatment Options
Tirzepatide
Mounjaro
- Dual GIP + GLP-1 receptor agonist
- Up to 22.5% weight loss (SURMOUNT-1)
- DermaVue first-line recommendation
Semaglutide
Ozempic / Wegovy
- Single GLP-1 receptor agonist
- Up to 14.9% weight loss (STEP 1)
- Proven safety profile since 2017
Oral Semaglutide
Rybelsus
- Daily oral tablet
- Good for maintenance phase
- Prescription only — assessed at consultation
Your Medical Team
Dr. Rejeesh Menon
MD (Internal Medicine) · US Faculty
Medical Director, SuperHuman
Dr. Sarath Chandran
MD DVL
Co-Founder & Managing Director
Dr. Minu Liz Mathew
MD DVL · RealSelf Recognized
Lead Dermatologist
SuperHuman Program — Available at All 7 DermaVue Clinics
Frequently Asked Questions
The SuperHuman Program is DermaVue's dermatologist-led, dietitian-supported medical weight loss program combining GLP-1 medications (Mounjaro/Tirzepatide or Ozempic/Semaglutide) with dermatologist skin protection, body composition monitoring, and nutrition guidance.
Patients with BMI ≥25 (Indian standard), or BMI 23–27 with metabolic risk factors such as prediabetes, high waist circumference, PCOS, or fatty liver. A doctor assessment determines eligibility after lab review.
Mounjaro (Tirzepatide) activates both GIP and GLP-1 receptors (dual mechanism), achieving up to 22.5% weight loss in the SURMOUNT-1 trial. Ozempic (Semaglutide) activates only GLP-1 receptors, achieving up to 14.9% in the STEP 1 trial. DermaVue recommends Mounjaro as first-line for most patients.
Start with a WhatsApp inquiry or book a consultation. Your first step is a 45–60 minute dietitian assessment, followed by a mandatory lab panel. Once labs are reviewed, your dermatologist creates a personalized GLP-1 treatment plan. The entire onboarding takes about 1–2 weeks.
Ozempic Face refers to facial volume loss that can occur with rapid weight loss on GLP-1 therapy. DermaVue's Face-Saver Protocol uses Profhilo bioremodeling at Month 2, Polynucleotides at Month 3, and MFU-V/Ultherapy from Month 6 to prevent and restore facial volume.
Yes, with appropriate medical screening. Indian consensus guidelines define overweight as BMI ≥23. GLP-1 therapy is particularly effective for the Indian thin-fat phenotype with central obesity and metabolic risk at normal Western BMI cutoffs.
Baseline labs include HbA1c, Fasting Insulin, HOMA-IR calculation, Complete Lipid Panel, TSH, LFT (ALT/AST), Kidney Function (eGFR), Vitamin D3, and B12. The lab form is sent after the dietitian consultation.
Without proper supervision, up to 45% of GLP-1 weight loss can be lean muscle. DermaVue's SuperHuman Program prevents this through protein optimization (1.2–1.6 g/kg ideal body weight), resistance training guidance, creatine supplementation, and monthly body composition tracking.
DERMAVUE SUPERHUMAN PROGRAM
Ready to Start Your SuperHuman Journey?
Talk to a doctor — free 10-minute WhatsApp consultation
★ 4.8 rating · 7,200+ patients · Dermatologist-led program
